Ligand Pharmaceuticals Incorporated Common Stock (NASDAQ:LGND)

Home >> Stock >> Ligand Pharmaceuticals Incorporated Common Stock >> Reports

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms....

+See More

Blog+More

Stock Synopsis: Life insurers emphasize profit margins over sales growth rates.

Fiona Sydney

2024-05-27 03:23:34 Monday ET

Stock Synopsis: Life insurers emphasize profit margins over sales growth rates.

Stock Synopsis: Life insurers emphasize profit margins over sales growth rates. We review and analyze the recent market share data in the U.S. life insur

+See More

President Trump picks David Malpass to run the World Bank to curb international multilateralism.

Rose Prince

2019-02-07 07:25:00 Thursday ET

President Trump picks David Malpass to run the World Bank to curb international multilateralism.

President Trump picks David Malpass to run the World Bank to curb international multilateralism. The Trump administration seems to prefer bilateral negotiat

+See More

Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2021.

Apple Boston

2021-02-02 14:24:00 Tuesday ET

Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2021.

Our proprietary alpha investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implement

+See More

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fundamental analysis of AT&T (U.S. stock symbol: $T).

Apple Boston

2025-10-05 17:31:00 Sunday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fundamental analysis of AT&T (U.S. stock symbol: $T).

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund

+See More

The current AI-driven stock market rally may not be an asset bubble yet.

Laura Hermes

2027-04-30 12:31:00 Friday ET

The current AI-driven stock market rally may not be an asset bubble yet.

In recent years, the current AI-driven stock market rally may or may not turn out to be another major asset bubble in global human history. For the pract

+See More

Agile lean enterprises remain flexible and capable of reinvention in light of new megatrends such as digitization and servitization.

Amy Hamilton

2020-10-20 09:36:00 Tuesday ET

Agile lean enterprises remain flexible and capable of reinvention in light of new megatrends such as digitization and servitization.

Agile lean enterprises remain flexible and capable of reinvention in light of new megatrends such as digitization and servitization. Shane Cragun and Kat

+See More